The first one was on Spiriva. I just wanted to check if you're hearing anything incrementally in terms of competition there and whether our FY27 guidance, sort of any potential generic?
The acquisition related cost which we have alluded to within other expenses, was that a meaningful figure this quarter?
Just to get your thoughts around some of the recent regulations that we've seen around PBMs in the U.S. My understanding is a large part of the benefit will probably flow down to the end customers, the payer. And this is largely neutral from a generic manufacturer standpoint. Now, is that how you also probably look at it? And could there be any change in term s of the industry mix, the rating levels, etcetera, which you probably foresee?
Just a second one, you typically call out the growth figure for Europe. So, if you could just share that for this quarter?
First one on Risperidone, which we plan to launch this quarter. I wanted to check if this is a shared CGT Exclusivity?
And on Mirabegron, I think I missed your comments. On base cases, no incremental competition in the near-term. Is that the right understanding?
My first question was on the margin front. So given the trajectory of gross margins and other expenses, is there any rating in terms of the medium-term margin aspirations or the medium-term margins that we're guiding to? I think I heard 22% to 23% this year. Beyond FY25 how are we looking at margins?
Secondly, just wanted to check if this quarter so far in A lbuterol, have you seen any impact of Amphastar ’s launch ? Though the company has been saying that they themselves don ’t expect meaningful contribution this quarter. But have you seen any impact so far?
This is Shashank from Emkay Global. Thanks for taking my question.
Yes. Is this better?